Charlie Bolten

Unleash Immuno Oncolytics, Inc. develops oncolytic virus immunotherapy products to treat cancer. Its product is UIO-512. the company is headquartered in Saint Louis, MO.

Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA.

Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO.

Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO.

Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO.

Impetus Agriculture, LLC is an American company that specializes in growing commercial biotech crops and developing bio pesticide formulations. The company was founded in 2018, and Martha Schlicher has been the CEO of the company since 2020.

Solis Agrosciences, Inc. is a plant sciences company located in the 39N Innovation District. The American company offers technology and research services to agricultural innovators with the goal of designing and delivering new biotech plant traits in multiple crops using their proprietary Plant Pipeline as a Service (PPaaS™) for gene-edited and transgenic plant generation and characterization. Solis has a team of experienced scientists, entrepreneurs, and agtech leaders to support research needs and accelerate agricultural innovation to solve food and climate challenges. The company was founded by Charlie W. Bolten and the CEO is Tom Cohen.

BioGenerator (Venture Capital) (BioGenerator) is a venture capital subsidiary of BioGenerator founded in 2003. The firm is headquartered in St. Louis, Missouri.

Elira, Inc. develops a system to suppress appetite and assist diet adherence. The company was founded by John Faul in 2015 and is headquartered in St. Louis, MO.

Impetus Agriculture, LLC is an American company that specializes in growing commercial biotech crops and developing bio pesticide formulations. The company was founded in 2018, and Martha Schlicher has been the CEO of the company since 2020.

Solis Agrosciences, Inc. is a plant sciences company located in the 39N Innovation District. The American company offers technology and research services to agricultural innovators with the goal of designing and delivering new biotech plant traits in multiple crops using their proprietary Plant Pipeline as a Service (PPaaS™) for gene-edited and transgenic plant generation and characterization. Solis has a team of experienced scientists, entrepreneurs, and agtech leaders to support research needs and accelerate agricultural innovation to solve food and climate challenges. The company was founded by Charlie W. Bolten and the CEO is Tom Cohen.

Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA.

Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO.

Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO.

Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO.

Elira, Inc. develops a system to suppress appetite and assist diet adherence. The company was founded by John Faul in 2015 and is headquartered in St. Louis, MO.

Solis Agrosciences, Inc. is a plant sciences company located in the 39N Innovation District. The American company offers technology and research services to agricultural innovators with the goal of designing and delivering new biotech plant traits in multiple crops using their proprietary Plant Pipeline as a Service (PPaaS™) for gene-edited and transgenic plant generation and characterization. Solis has a team of experienced scientists, entrepreneurs, and agtech leaders to support research needs and accelerate agricultural innovation to solve food and climate challenges. The company was founded by Charlie W. Bolten and the CEO is Tom Cohen.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA.

Elira, Inc. develops a system to suppress appetite and assist diet adherence. The company was founded by John Faul in 2015 and is headquartered in St. Louis, MO.

Edison Agrosciences, Inc. provides agricultural biotechnology services. The firm specializes in agriculture, biotechnology and rubber. The company was founded by Matthew B. Crisp and Thomas M. Hohn and is headquartered in Creve Coeur, MO.

Edison Agrosciences, Inc. provides agricultural biotechnology services. The firm specializes in agriculture, biotechnology and rubber. The company was founded by Matthew B. Crisp and Thomas M. Hohn and is headquartered in Creve Coeur, MO.

Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

BioGenerator (Venture Capital) (BioGenerator) is a venture capital subsidiary of BioGenerator founded in 2003. The firm is headquartered in St. Louis, Missouri.

Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO.

Solis Agrosciences, Inc. is a plant sciences company located in the 39N Innovation District. The American company offers technology and research services to agricultural innovators with the goal of designing and delivering new biotech plant traits in multiple crops using their proprietary Plant Pipeline as a Service (PPaaS™) for gene-edited and transgenic plant generation and characterization. Solis has a team of experienced scientists, entrepreneurs, and agtech leaders to support research needs and accelerate agricultural innovation to solve food and climate challenges. The company was founded by Charlie W. Bolten and the CEO is Tom Cohen.

Impetus Agriculture, LLC is an American company that specializes in growing commercial biotech crops and developing bio pesticide formulations. The company was founded in 2018, and Martha Schlicher has been the CEO of the company since 2020.

Solis Agrosciences, Inc. is a plant sciences company located in the 39N Innovation District. The American company offers technology and research services to agricultural innovators with the goal of designing and delivering new biotech plant traits in multiple crops using their proprietary Plant Pipeline as a Service (PPaaS™) for gene-edited and transgenic plant generation and characterization. Solis has a team of experienced scientists, entrepreneurs, and agtech leaders to support research needs and accelerate agricultural innovation to solve food and climate challenges. The company was founded by Charlie W. Bolten and the CEO is Tom Cohen.

Impetus Agriculture, LLC is an American company that specializes in growing commercial biotech crops and developing bio pesticide formulations. The company was founded in 2018, and Martha Schlicher has been the CEO of the company since 2020.

BioGenerator (Venture Capital) (BioGenerator) is a venture capital subsidiary of BioGenerator founded in 2003. The firm is headquartered in St. Louis, Missouri.

BioGenerator (Venture Capital) (BioGenerator) is a venture capital subsidiary of BioGenerator founded in 2003. The firm is headquartered in St. Louis, Missouri.

Solis Agrosciences, Inc. is a plant sciences company located in the 39N Innovation District. The American company offers technology and research services to agricultural innovators with the goal of designing and delivering new biotech plant traits in multiple crops using their proprietary Plant Pipeline as a Service (PPaaS™) for gene-edited and transgenic plant generation and characterization. Solis has a team of experienced scientists, entrepreneurs, and agtech leaders to support research needs and accelerate agricultural innovation to solve food and climate challenges. The company was founded by Charlie W. Bolten and the CEO is Tom Cohen.

Solis Agrosciences, Inc. is a plant sciences company located in the 39N Innovation District. The American company offers technology and research services to agricultural innovators with the goal of designing and delivering new biotech plant traits in multiple crops using their proprietary Plant Pipeline as a Service (PPaaS™) for gene-edited and transgenic plant generation and characterization. Solis has a team of experienced scientists, entrepreneurs, and agtech leaders to support research needs and accelerate agricultural innovation to solve food and climate challenges. The company was founded by Charlie W. Bolten and the CEO is Tom Cohen.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

Unleash Immuno Oncolytics, Inc. develops oncolytic virus immunotherapy products to treat cancer. Its product is UIO-512. the company is headquartered in Saint Louis, MO.

Impetus Agriculture, LLC is an American company that specializes in growing commercial biotech crops and developing bio pesticide formulations. The company was founded in 2018, and Martha Schlicher has been the CEO of the company since 2020.

Impetus Agriculture, LLC is an American company that specializes in growing commercial biotech crops and developing bio pesticide formulations. The company was founded in 2018, and Martha Schlicher has been the CEO of the company since 2020.

Elira, Inc. develops a system to suppress appetite and assist diet adherence. The company was founded by John Faul in 2015 and is headquartered in St. Louis, MO.

Unleash Immuno Oncolytics, Inc. develops oncolytic virus immunotherapy products to treat cancer. Its product is UIO-512. the company is headquartered in Saint Louis, MO.

Elira, Inc. develops a system to suppress appetite and assist diet adherence. The company was founded by John Faul in 2015 and is headquartered in St. Louis, MO.

Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO.

Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO.

Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO.

Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA.

Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO.

Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO.

BioGenerator (Venture Capital) (BioGenerator) is a venture capital subsidiary of BioGenerator founded in 2003. The firm is headquartered in St. Louis, Missouri.